Theravance Biopharma, Inc. Income Statement
TBPH / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 14 fiscal years. All figures from audited SEC 10-K filings.
Theravance Biopharma, Inc. reported $107M in revenue and $106M in net income for FY2025. Revenue has declined at a 1.5% compound annual rate over the past 13 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $71.9M | $55.3M | $71.9M | $15.4M | $48.6M | $3.1M | $48.6M | $226.0K | $130.1M | $226.0K | $130.1M |
| Cost of Revenue | - | - | - | - | - | - | - | - | $6.0M | $2.9M | $0 | $0 | $0 | $0 |
| SG&A Expense | $73.7M | $69.2M | $70.1M | $108.5M | $99.3M | $108.5M | $95.6M | $84.5M | $95.6M | $84.5M | $35.9M | $25.7M | $35.9M | $25.7M |
| R&D Expense | $37.4M | $37.6M | $40.6M | $261.0M | $193.7M | $261.0M | $173.9M | $141.7M | $173.9M | $141.7M | $120.6M | $114.0M | $120.6M | $114.0M |
| Operating Income | -$3.6M | -$46.9M | -$56.0M | -$297.6M | -$257.8M | -$297.6M | -$260.1M | -$180.5M | -$260.1M | -$180.5M | -$156.3M | -$9.6M | -$156.3M | -$9.6M |
| Interest Expense | - | - | $2.4M | $8.5M | $8.5M | $8.5M | $8.5M | $1.4M | $8.5M | $1.4M | - | - | - | - |
| Income Tax | $23.4M | $11.8M | $5.9M | -$8.5M | -$151.0K | -$8.5M | $13.7M | $10.1M | $13.7M | $10.1M | $0 | $0 | $0 | $0 |
| Net Income | $105.9M | -$56.4M | -$55.2M | -$278.0M | -$199.4M | -$278.0M | -$285.4M | -$190.7M | -$285.4M | -$190.7M | -$156.3M | -$9.6M | -$156.3M | -$9.6M |
| EPS (Basic) | -$1.15 | -$1.00 | $11.85 | -$4.46 | -$4.25 | - | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$1.15 | -$1.00 | $11.85 | -$4.46 | -$4.25 | -$3.99 | -$5.45 | -$4.26 | -$5.34 | -$7.46 | -$4.92 | -$0.30 | - | - |
| Shares Outstanding | 49.5M | 48.1M | 65.2M | 74.4M | 64.3M | 57.0M | 55.7M | 54.4M | 52.8M | 38.0M | 32.2M | 0 | 31.7M | 31.7M |
| Operating Margin | -3.4% | -72.9% | -97.6% | -414.2% | -466.1% | -414.2% | -1690.7% | -371.0% | -8426.4% | -371.0% | -69152.2% | -7.4% | - | -7.4% |
| Profit Margin | 98.5% | -87.6% | -96.1% | -386.9% | -360.6% | -386.9% | -1855.0% | -391.9% | -9245.4% | -391.9% | -69152.2% | -7.4% | - | -7.4% |